| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.4B | ¥7.9B | -81.6% |
| Operating Income | ¥-5.4B | ¥0.9B | -700.0% |
| Ordinary Income | ¥-5.2B | ¥1.2B | -525.4% |
| Net Income | ¥-5.2B | ¥0.8B | -719.0% |
| ROE | -47.1% | 5.3% | - |
FY2026 Q3 results show severe deterioration with revenue of 1.4 billion yen (YoY -81.6%), operating loss of -5.4 billion yen (prior year profit of 0.9 billion yen, YoY -700.0%), ordinary loss of -5.2 billion yen (prior year profit of 1.2 billion yen, YoY -525.4%), and net loss of -5.2 billion yen (prior year profit of 0.8 billion yen, YoY -719.0%). The company maintained a gross margin of 90.8% at 1.3 billion yen, but SG&A expenses of 6.7 billion yen significantly exceeded revenue, driving the operating loss. Non-operating income of 0.2 billion yen including FX gains of 0.3 billion yen partially offset losses, resulting in ordinary loss of -5.2 billion yen. Basic EPS deteriorated to -20.20 yen from 3.30 yen YoY. Despite these losses, balance sheet liquidity remains strong with cash and deposits of 11.8 billion yen representing 70.7% of total assets of 16.7 billion yen, and equity ratio of 66.1%, though retained earnings declined to -5.7 billion yen from -0.5 billion yen prior year.
Revenue collapsed by 81.6% from 7.9 billion yen to 1.4 billion yen, indicating a fundamental shift in business structure or timing of sales recognition. The company maintained a high gross margin of 90.8% with cost of sales of only 0.1 billion yen, suggesting the core product economics remain intact. However, SG&A expenses of 6.7 billion yen overwhelmed the 1.3 billion yen gross profit, representing 463.6% of revenue and creating an operating loss of -5.4 billion yen versus prior year operating profit of 0.9 billion yen. The dramatic increase in SG&A burden relative to revenue indicates fixed cost structure unable to flex with revenue decline. Non-operating items contributed positively with 0.2 billion yen net gain, primarily from FX gains of 0.3 billion yen and interest income of 0.0 billion yen. Ordinary loss reached -5.2 billion yen versus prior year ordinary profit of 1.2 billion yen, representing a swing of 6.4 billion yen. Tax expense was minimal at 0.0 billion yen given the loss position, resulting in net loss of -5.2 billion yen. The gap between operating loss (-5.4 billion yen) and ordinary loss (-5.2 billion yen) of approximately 0.2 billion yen reflects the modest cushion from non-operating income. This represents a revenue down/profit down pattern, with the profitability deterioration significantly outpacing the revenue decline due to operating leverage and fixed cost rigidity.
[Profitability] ROE of -47.1% reflects severe earnings deterioration, compared to the pharma industry median of -35.8% in 2025-Q3, indicating performance below industry peers. Operating margin of -372.4% significantly underperforms the industry median of -218.2%, representing one of the lowest margins in the sector. Net profit margin of -358.6% also trails the industry median of -216.8%. Asset turnover of 0.087 times falls below the industry median of 0.17, indicating weak asset utilization efficiency. Financial leverage of 1.51 times aligns closely with the industry median of 1.47. [Cash Quality] Cash and deposits of 11.8 billion yen provide coverage of 2.31 times current liabilities of 5.1 billion yen, with current ratio of 316.7% substantially exceeding the industry median of 6.62 times when expressed consistently. [Investment Efficiency] Total asset turnover of 0.087 indicates low revenue generation per asset base. Receivables turnover days increased significantly as trade receivables declined from 5.5 billion yen to 0.1 billion yen, moving faster than the industry median of 151.55 days. [Financial Health] Equity ratio of 66.1% slightly trails the industry median of 67.8% but remains healthy. Current ratio of 316.7% demonstrates strong short-term liquidity. Debt-to-equity ratio of 4.5% indicates conservative leverage with long-term loans of 0.5 billion yen representing minimal financial risk.
Cash and deposits increased from prior period levels to 11.8 billion yen, representing 70.7% of total assets and providing substantial liquidity buffer despite operating losses. The balance sheet shows significant working capital efficiency changes, with trade receivables declining 97.9% from 5.5 billion yen to 0.1 billion yen, and trade payables declining 96.9% from 1.4 billion yen to 0.0 billion yen, suggesting fundamental changes in sales and procurement cycles coinciding with the revenue collapse. Inventories remained relatively stable at 0.1 billion yen. Current assets of 16.3 billion yen consist predominantly of cash, indicating liquidity is not locked in operating assets. The operating loss position implies cash consumption from operations, though the strong cash balance of 11.8 billion yen provides coverage of 2.31 times short-term debt and current liabilities of 5.1 billion yen combined. Long-term loans remained modest at 0.5 billion yen. The dramatic reduction in receivables and payables suggests either business model transition or timing effects around quarter-end. Retained earnings declined 5.2 billion yen to -5.7 billion yen, directly reflecting the net loss and indicating equity erosion that will require monitoring if losses continue.
Ordinary loss of -5.2 billion yen versus operating loss of -5.4 billion yen shows net non-operating contribution of approximately 0.2 billion yen, representing 14% of revenue. Non-operating income comprises primarily FX gains of 0.3 billion yen and interest income of 0.0 billion yen, partially offset by minimal non-operating expenses of 0.0 billion yen. The FX gains appear as a one-time favorable item and should not be considered recurring. Non-operating income of 0.2 billion yen represents 14% of revenue, indicating moderate reliance on non-core items relative to the operating loss. The gross margin of 90.8% suggests healthy underlying product economics, but the SG&A burden of 463.6% of revenue overwhelms this, pointing to a structural cost issue rather than product margin deterioration. Extraordinary losses were minimal at 0.0 billion yen with no significant asset disposals or impairments recorded. The quality of earnings is weak given the operating loss position, though the high cash balance suggests near-term financial stability is maintained. Without operating cash flow disclosure, the cash generation quality cannot be directly assessed, though the negative net income and reduction in working capital assets implies cash consumption from operations during the period.
Full-year guidance projects revenue of 2.0 billion yen (YoY -85.3%), operating loss of -7.6 billion yen, ordinary loss of -7.4 billion yen, and net loss of -7.4 billion yen with EPS forecast of -28.68 yen. Q3 cumulative progress rates cannot be calculated from single quarter data, but Q3 revenue of 1.4 billion yen represents 70% of the full-year forecast of 2.0 billion yen, suggesting Q4 revenue is expected at only 0.6 billion yen. Q3 operating loss of -5.4 billion yen represents 71% of the full-year operating loss forecast of -7.6 billion yen, implying Q4 operating loss of approximately -2.2 billion yen. The guidance indicates the company expects continued losses through year-end but at a moderating rate in Q4. The revenue forecast of 2.0 billion yen for the full year down 85.3% YoY suggests a fundamental business transition or restructuring is underway. The dividend forecast of 0.00 yen confirms no shareholder distribution during this loss period. No guidance revision was disclosed this quarter, indicating the company is tracking to its previously announced expectations for significant contraction and losses.
Revenue concentration risk with 81.6% YoY decline indicating heavy dependence on limited sales channels or customers, with potential disruption in core business model requiring urgent diversification or recovery measures. Operating leverage risk as SG&A expenses of 6.7 billion yen far exceed revenue of 1.4 billion yen (463.6% ratio), creating cash burn that will deplete the 11.8 billion yen cash reserve if sustained, requiring immediate cost restructuring. Equity erosion risk with retained earnings declining to -5.7 billion yen and continued losses forecast, potentially requiring capital injection or debt financing if turnaround is delayed, though current equity ratio of 66.1% provides buffer.
[Industry Position] (Reference - Proprietary Analysis) The company's performance metrics substantially underperform pharma industry benchmarks across profitability and efficiency dimensions. Profitability indicators including ROE of -47.1% (Industry Median -35.8%), Operating Margin of -372.4% (Industry Median -218.2%), and Net Profit Margin of -358.6% (Industry Median -216.8%) all rank in the bottom quartile, indicating severe operational challenges relative to peers. Efficiency metrics show Asset Turnover of 0.087 times versus Industry Median of 0.17, placing the company below median in capital productivity. Financial Health metrics are relatively stronger, with Equity Ratio of 66.1% close to the Industry Median of 67.8%, and Current Ratio of 316.7% significantly exceeding the industry norm, indicating the company maintains superior liquidity despite earnings weakness. Financial Leverage of 1.51 times aligns with Industry Median of 1.47, showing balanced capital structure. The company's Revenue Growth YoY of -81.6% dramatically underperforms the Industry Median decline of -12.5%, suggesting company-specific challenges beyond sector headwinds. (Industry: Pharmaceutical, Comparison: 2025-Q3, Source: Proprietary analysis of 13 companies)
Structural revenue collapse of 81.6% YoY to 1.4 billion yen represents the most critical issue, requiring confirmation of whether this reflects temporary sales timing, customer concentration loss, or permanent business model shift, with Q4 recovery trajectory being the key monitoring point. Despite severe losses, balance sheet resilience remains notable with cash and deposits of 11.8 billion yen providing 2.31 times coverage of current liabilities, offering runway for restructuring, though the 6.7 billion yen annual SG&A run rate implies less than two years of cash runway at current burn rate absent revenue recovery. The 90.8% gross margin preservation indicates core product value proposition remains intact, suggesting the path to recovery centers on revenue restoration and SG&A rationalization rather than fundamental product economics, making cost reduction execution and sales pipeline visibility the two critical factors for turnaround assessment.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.